Randomized Phase 3 Study of Pomalidomide-Cyclophosphamide-Dexamethasone (PCD) Versus Pomalidomide-Dexamethasone (PD) in Relapse or Refractory Myeloma. An AMN Study

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 06 Jun 2022

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Cyclophosphamide (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Pomalidomide (Primary)
Indications Multiple myeloma
Focus Therapeutic Use
Acronyms An AMN Study

08 Dec 2020 Interim results (n=46; data cut-off date - 24 June 2020) of phase 3 study of pomalidomide with cyclophosphamide and dexamethasone versus pomalidomide and dexamethasone in asian patients, presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
01 Nov 2017 Status changed from not yet recruiting to recruiting.
10 May 2017 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com